News and Trends 29 Aug 2016
Sanofi’s Phase III Results could make Praluent the next Blockbuster Cholesterol Drug
If you’re only just recovering from Pfizer’s inescapable ad campaign for Lipitor, brace yourself: Sanofi and Regeneron are poised to introduce its successor, Praluent (alirocumab), following its excellent Phase III results. Heart disease is the leading cause of death in Americans over the age of 35, and it contributes significantly to the global mortality rate. […]